Human trials of vagus nerve stimulation (VNS) for Parkinson's have reached small pilot studies of neck and ear devices for gait and motor symptoms. VNS sends mild electrical pulses to the vagus nerve through the neck or ear, and no VNS treatment is approved for Parkinson's. Researchers have tested cervical noninvasive VNS and transcutaneous auricular VNS, called taVNS, in groups of seven to 36 patients. Benefits remain investigational, with larger dose-finding trials still underway.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which neck-device trial tested freezing of gait?
- What did brain and motor-circuit studies show?
- Has ear stimulation been safe and feasible?
- What should readers trust and watch next?
Which neck-device trial tested freezing of gait?
In 36 Parkinson's patients with freezing of gait, one month of thrice-daily cervical noninvasive VNS with gammaCore improved walking speed 16%, step length 11% and step time versus sham. NeurologyLive reported the randomized double-blind crossover result in the June 2021 trial summary.
The crossover design means each participant received both active and sham stimulation in separate periods. That structure helps isolate stimulation effects in a small group.
What did brain and motor-circuit studies show?
University of Oxford MRC Brain Network Dynamics Unit researchers studied seven patients with simultaneous subthalamic recordings. Left cervical noninvasive VNS progressively reduced abnormal low-beta brain activity, peaking after the fourth stimulation block.
In a separate study, npj Parkinson's Disease/Nature reported 32 patients versus 20 healthy controls after two weeks of ear-based taVNS. Right motor-cortex nodal efficiency rose and intracortical facilitation increased, correlating with lower UPDRS-III motor scores.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
Has ear stimulation been safe and feasible?
In U.S. patients receiving 10 in-office ear-VNS sessions over two weeks, multi-session taVNS was safe, feasible and well tolerated.
Frontiers in Neurology described no serious adverse events in the 2023 safety and feasibility report. These were supervised clinic sessions, not unsupervised home use. Reviewers concluded home devices still need optimized stimulation parameters before routine clinical use.
What should readers trust and watch next?
Readers should set aside one widely shared 2021 gammaCore biomarker report. PubMed Central now labels that gait, TNF-alpha, glutathione and BDNF paper as retracted in the retraction notice, so its efficacy claims cannot be relied upon.
Registered trials listed by ClinicalTrials.gov are now testing taVNS doses for gait, including 25-Hz versus 100-Hz versus sham, plus twice-daily 30-minute courses for sleep and non-motor symptoms in the registered dose-comparison trial. Practical steps for interested patients and caregivers are:.
- Bring freezing of gait, falls and sleep symptoms to your neurologist before seeking stimulation.
- Ask whether a local Parkinson's taVNS trial is enrolling and what time commitment it requires.
- Do not buy a neck or ear device for Parkinson's or change medication to try stimulation.
You Might Also Like
- Deep Brain Stimulation and Exercise: Does Movement Therapy Still Help After Surgery?
- Tai Chi for Parkinson’s Balance: What a Neurologist Looks For
- Dopamine and Exercise: How Movement Affects Parkinson’s Medication Response